RxDoctor Payments DataLook up a doctor →

Karima Peretti, PA

Physician Assistant · Manchester, NHNPI 1437652138

Payments from drug & device makers

$13,971in general payments, 2019–2025

Across 692 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$852
  • plus $6K from 25 others

What the payments were for

  • Food & beverage$13,50197%
  • Education$4703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,971 in reported general payments places this provider in the 95th percentile of 782 physician assistant providers in New Hampshire.

See all physician assistant providers in New Hampshire

Medicare billing

Part B allowed, 2024
$225,536
Medicare patients
613
Services billed
3,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab35$201,890
OpzeluraRuxolitinib Phosphate24$49,056
ZoryveRoflumilast11$9,231
Clobetasol Propionate138$6,351
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc55$3,253
Fluorouracil59$3,021
Tacrolimus31$2,985
Ketoconazole207$2,574
Doxycycline Hyclate68$1,920
Metronidazole34$1,425
Tretinoin22$1,399
Econazole Nitrate41$923
Ciclopirox19$800
Triamcinolone Acetonide119$761
Clindamycin Phosphate36$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$487$49,05624 claims
Arcutis Biotherapeutics, Inc.Zoryve$475$9,23111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 782 physician assistant providers in New Hampshire.

Other physician assistant in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →